Plasma Circular-RNA 0005567 as a Potential Marker of Disease Activity in Rheumatoid Arthritis

Circular RNAs (circRNAs) are noncoding molecules and are generated through back splicing, during which the 5' and 3' ends are covalently joined. Consequently, the lack of free ends makes them stable and resistant to exonucleases, and they become more suitable biomarkers than other noncoding RNAs. The aim of the study was to find an association between selected circRNAs and disease activity in patients with RA. A total of 71 subjects, 45 patients with RA and 26 healthy controls (HCs), were enrolled. In the RA group, 24 patients had high disease activity (DAS-28-ESR > 5.1) and 21 individuals were in remission (DAS-28-ESR ≤ 2.6). The cell line SW982 was used to evaluate the biological function of circ_0005567. The concentration of circ_0005567 in RA patients was elevated compared to HCs (median, 177.5 [lower-upper quartile, 83.13-234.6] vs. 97.83 [42.03-145.4], p = 0.017). Patients with high disease activity had a higher concentration of circ_0005567 than the control group (185.4 [112.72-249.25] vs. 97.83 [42.03-145.4], p = 0.015). In the cell line model, we found an association between circ_0005567 and miR-194-5p concentration and increased expression of mRNAs that may be related to cell proliferation. The plasma concentration of circ_0005567 may be a new potential biomarker associated with disease activity in patients with RA.

Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report

BACKGROUND

The introduction of tumor necrosis factor (TNF) antagonists (adalimumab, infliximab, and etanercept) was a major advance and was highly important and beneficial in most rheumatoid arthritis (RA) patients. The adverse effects of this treatment are infrequent, but include opportunistic intracellular infection (especially the reactivation of latent Mycobacterium tuberculosis); exacerbation of demyelinating disorders; and the production of various types of antibodies such as antinuclear antibodies (ANA) or double-stranded DNA autoantibodies (dsDNA) and antiphospholipid antibodies (aPL) such as anti-cardiolipin antibodies (aCL) and anti-B2GP-I antibodies (B2GP-I). The aim of the study was to determine the prevalence of aCL and B2GP-I in IgM and IgG classes, using ELISA tests, during 6 months of follow-up in patients with refractory RA successfully treated with infliximab.

MATERIAL/METHODS

We determined the prevalence of aCL and B2GP-I in IgM and IgG classes, using ELISA tests, during 6 months of follow-up in patients with refractory RA successfully treated with infliximab.

RESULTS

We observed a statistically important increase only in the group of B2GP-I IgM (p<0.05). There are contradictory results concerning the ability of infliximab to induce aPL, but most authors confirm this phenomenon.

CONCLUSIONS

Further investigations are needed to determine if the new aPL appears in patients with β2-GPI gene polymorphisms such as leucine-to-valine substitution at position 247, which can lead to a conformational changes in β2-GPI protein, leading to aPL synthesis. The role of aPL in pathogenesis of APS is still unclear, but we should remember the immunogenic aspect of TNF antagonist treatment. Therefore, we recommend early detection of aPL and observation of the patient, paying special attention to signs and symptoms of thromboembolism.

PP069. The expressions of B7-H1 and B7-H4 co-stimulatory molecules on myeloid and lymphoid dendritic cells in pre-eclampsia and normal pregnancy. The expressions of B7-H1 and B7-H4 co-stimulatory moleculeson myeloid and lymphoid dendritic cells in pre-eclampsia and normal pregnancy

INTRODUCTION

Pre-eclampsia (PE) is a common obstetric syndrome affecting about 5-10% of pregnant women. The syndrome is a leading cause of maternal and fetal morbidity and mortality, even in developed world. The etiology and pathogenesis of this syndrome are not fully understood. There are many studies describing alterations in the innate and adaptive immune system which may have an influence on the onset of this disorder. It was suggested that activation of cell-mediated immunity may play the key role in the etiology of pre-eclampsia.

OBJECTIVES

The purpose of our study was to estimate the expressions of B7-H1 and B7-H4 costimulatory molecules on myeloid and lymphoid DCs (CD1c(+), BDCA-2(+)) in the peripheral blood of patients with pre-eclampsia and normal pregnant women in the third trimesters of physiological pregnancy.

METHODS

Thirty three patients with pre-eclampsia and 26 normal pregnant women were included in the study. Dendritic cells were isolated from peripheral blood, stained with monoclonal antibodies against blood dendritic cell antigens and B7-H1 and B7-H4 molecules and estimated using flow cytometry.

RESULTS

The expressions of B7-H1 molecule on CD1c(+) myeloid DCs and B7-H4 molecule on BDCA-2(+) lymphoid DCs did not differ in pre-eclampsia and healthy third trimester pregnant women. The expressions of B7-H4 molecule on CD1c(+) myeloid DCs and B7-H1 molecule on BDCA-2(+) lymphoid DCs were significantly higher in peripheral blood of patients with pre-eclampsia in comparison with the control group.

CONCLUSION

It seems possible that higher expressions of B7-H4 molecule on CD1c(+) myeloid DCs and B7-H1 molecule on lymphoid BDCA-2(+) DCs in pre-eclampsia may be the tolerogenic mechanism secondary to the pro-inflammatory response which is observed in this syndrome.

OS007. The apoptosis markers are altered in CD4(+)CD25(+)FOXP3(+) T regulatorylymphocytes in pre-eclampsia

INTRODUCTION

Pre-eclampsia (PE) is a common obstetric syndrome affecting about 5-10% of pregnant women. The etiology and pathogenesis of this syndrome are not fully understood. There are many studies describing alterations in the innate and adaptive immune system which may have an influence on the onset of this disorder. It was suggested that the activation of cell-mediated immunity may play the key role in the etiology of pre-eclampsia. It was proposed that inappropriate activation of the immune system can lead to pre-eclampsia.

OBJECTIVES

The aim of our study was to estimate the surface expressions of CD95(APO-1/Fas) antigen and the intracellular expressions of anti-apoptotic proteinBcl-2 and pro-apoptotic proteinBax in CD4(+)CD25(+)FoxP3(+) T regulatory lymphocytes (Tregs) as well as the percentage of CD8(+)CD28(+) T cytotoxic cells in peripheral blood of patients with pre-eclampsia in comparison with healthy pregnant women in the third trimester of physiological pregnancy.

METHODS

Twenty-four women with pre-eclampsia and twenty normal third trimester pregnant women were included in the study. The lymphocytes were isolated from peripheral blood samples and labelled with monoclonal antibodies. The expressions of surface antigens and intracellular proteins were estimated using flow cytometry.

RESULTS

The population of CD4(+)CD25(+)FoxP3(+) Treg cells was significantly lower in peripheral blood of patients with pre-eclampsia when compared to normal third trimester pregnant women. The percentages of CD4(+)CD25(+)FoxP3(+) Treg cells that express Bcl-2 protein were significantly lower in peripheral blood of patients with pre-eclampsia when compared to healthy pregnant women, whereas the percentages of CD4(+)CD25(+)FoxP3(+) Treg cells with the expressions of Bax protein did not differ in both groups. Moreover, the mean fluorescence intensity (MFI) of Bcl-2 protein in CD4(+)CD25(+)FoxP3(+) Treg cells was significantly lower and MFI of Bax protein significantly higher in pre-eclampsia when compared to the control group. The percentage of CD8(+)CD28(+) T cells did not differ in both studied groups but MFI of CD28 antigen on T CD8(+) cells was significantly higher in pre-eclampsia when compared to the control group.

CONCLUSION

The obtained results suggest that the deficit of CD4(+)CD25(+)FoxP3(+) Treg lymphocytes which is observed in pre-eclampsia maybe associated with alterations in apoptosis markers.

The expressions of CD200 and CD200R molecules on myeloid and lymphoid dendritic cells in pre-eclampsia and normal pregnancy

PROBLEM

The purpose of our study was to test the hypothesis that the expressions of CD200 and CD200R tolerance molecules are increased on peripheral blood dendritic cells (DCs) in normal pregnancy and decreased on peripheral blood DCs in pre-eclampsia.

METHOD OF STUDY

Thirty-three patients with pre-eclampsia, 38 normal pregnant women, and 10 healthy non-pregnant women were included in the study. Dendritic cells were isolated from peripheral blood, stained with monoclonal antibodies against blood dendritic cell antigens as well as CD200 and CD200R antigens, and estimated using flow cytometry.

RESULTS

The expressions of CD200 and CD200R molecules on CD1c(+) myeloid and BDCA-2(+) lymphoid DCs in the first trimester of normal pregnancy were significantly higher when compared to the luteal phase of the ovarian cycle. The expressions of CD200 molecule on CD1c(+) myeloid DCs were significantly lower in the third trimester of normal pregnancy when compared to the second trimester. The expressions of CD200R molecule on CD1c(+) myeloid DCs and BDCA-2(+) lymphoid DCs did not differ in pre-eclampsia and healthy third trimester pregnant women. However, the expressions of CD200 molecule on CD1c(+) myeloid and BDCA-2(+) lymphoid DCs were significantly higher in pre-eclampsia when compared to the healthy third trimester pregnant women.

CONCLUSION

The results suggest increased tolerogenic properties of myeloid and lymphoid DCs in normal human pregnancy. Moreover, they suggest a decrease in tolerogenic properties of DCs before delivery. It seems possible that higher expressions of CD200 molecule on CD1c(+) myeloid and BDCA-2(+) lymphoid DCs in pre-eclampsia may constitute the tolerogenic mechanism secondary to the pro-inflammatory response that is observed in this syndrome.